Ken Griffin Instil Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.63 $880 - $1,386	-2,200 Reduced 19.13%	9,300 $3,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $0.67 $3,009 - $3,953	-5,900 Reduced 33.91%	11,500 $6,000
Q1 2023 May 15, 2023	BUY	$0.6 - $0.91 $7,920 - $12,012	13,200 Added 314.29%	17,400 $11,000
Q4 2022 Feb 14, 2023	BUY	$0.48 - $5.33 $2,016 - $22,386	4,200 New	4,200 $2,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $8.8B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.